There is more than one kind of myofibroblast: Analysis of CD34 expression in benign, in situ, and invasive breast lesions

Journal of Clinical Pathology

Volumn 56, Issue 4, 2003, Pages 271-276

  Chauhan, H ^b   Abraham, A ^b   Phillips, J R A ^a   Pringle, J H ^a   Walker, R A ^a   Jones, J L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; BREAST BIOPSY; BREAST CARCINOMA; BREAST LESION; CANCER GRADING; CONTROLLED STUDY; DUCTAL CARCINOMA IN SITU; EPITHELIUM HYPERPLASIA; FEMALE; FIBROADENOMA; FIBROBLAST; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFILTRATING DUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

ACTINS; ANTIGENS, CD34; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; FIBROADENOMA; FIBROBLASTS; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS;

EID: 0344942634     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.4.271     Document Type: Article

References (46)

1. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69-125.
2. Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998;3:215-25.
3. Martin M, Pujuguet P, Martin F. Role of stromal myofibroblasts infiltrating colon cancer in tumour invasion. Pathol Res Pract 1996;192:712-17.
4. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
5. Popowicz P, Engel G, Wilking N, et al. Differential effects of fibroblast coculture on MCF-7 and MDA-MB-231 breast carcinoma cell invasion through Matrigel. Oncol Rep 1995;2:303-6.
6. Saiki I, Murata J, Yoneda J, et al. Influence of fibroblasts on the invasion and migration of highly or weakly metastatic B16 melanoma cells. Int J Cancer 1994;56:867-73.
7. Dimanche-Boitrel MT, Vakaet L, Pujuguet P, et al. In-vivo and in-vitro invasiveness of a rat colon-cancer cell-line maintaining E-cadherin expression - an enhancing role of tumour-associated myofibroblasts. Int J Cancer 1994;56:512-21.
8. Lengyel E, Gum R, Juarez J, et al. Induction of MR-92,000 type-IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 1995;55:963-7.
9. Ornstein DL, MacNab J, Cohn KH. Evidence for tumour-host cooperation in regulating MMP-2 expression in human colon cancer. Clin Exp Met 1999;17:205-12.
10. Polette M, Gilles C, Marchand V, et al. Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis 1997;15:157-63.
11. Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer 1999;80:315-21.
12. Poulsom R, Hanby AM, Pignatelli M, et al. Expression of gelatinase-A and TIMP-2 messenger-RNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993;46:429-36.
13. Heppner KJ, Matrisian LM, Jensen RA, et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumour-induced host response. Am J Pathol 1996;149:273-82.
14. Kurose K, Hoshaw-Woodard S, Adeyinka A, et al. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: dues to tumour-microenvironment interactions. Hum Mol Genet 2001;10:1907-13.
15. Cooke PS, Buchanan DL, Young P, et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A 1997;94:6536-40.
16. Silberstein GB. Tumour-stromal interactions: role of the stroma in mammary development. Breast Cancer Res 20001;3:218-23.
17. Tuxhorn JA, McAlhany SJ, Dang TD, et al. Stromal cells promote angiogenesis and growth of human prostate tumours in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002;62:3298-307
18. Shekhar MPV, Werdell J, Santner SJ, et al. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res 2001;61:1320-6.
19. Adams M, Jones JL, Walker RA, et al. Changes in Tenascin-C isoform expression in invasive and pre-invasive breast disease. Cancer Res 2002;62:3289-97.
20. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704
21. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-8.
22. Gabbiani G, Hirschel BJ, Ryan GB, et al. Granulation tissue as a contractile organ: a study of structure and function. J Exp Med 1972;135:719-34.
23. Grinnell F. Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 1994;124:401-4.
24. Silverman JS, Tamsen A. Mammary fibroadenomas and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIla+ dendrophages. Histopathology 1996;29:411-19.
25. Schor SL, Schor AM. Clonal heterogeneity in fibroblasts: implications for the control of epithelial-mesenchymal interactions. Bioessays 1987;7:200-4.
26. Gleave M, Hsieh J-T, Gao C, et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
27. Lindahl P, Betscholtz C. Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B using PDGF targeted mice. Curr Opin Nephrol Hypertens 1998;7:21-6.
28. van de Rijn M, Rouse RV. CD34. A review. Appl Immunohistochem 1994;2:71-80.
29. Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;12:2417-26.
30. Yamazaki K, Eyden BP. Ultrastructural and immunohistochemical observations on intralobular fibroblasts af human breast with observations on the CD34 antigen. J Submicrosc Cytol Pathol 1995;27:309-23.
31. Lanza F, Healy L, Sutherland DR. Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents 2001;15:1-13.
32. Magro G, Michal M, Bisceglia M. Benign spindle cell tumours of the mammary stroma: diagnostic criteria, classification and histogenesis. Pathol Res Pract 2001;197:453-66.
33. Moore T, Lee AHS. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. Histopathology 2001;38:62-76.
34. Lee AH, Dublin EA, Bobrow LG. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol 1999;187:285-90.
35. Chen CM, Chen CJ, Chang CL, et al. CD34, CD117 and actin expression in phyllodes tumour of the breast. J Surg Res 2000;94:84-91.
36. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protruberans: a reappraisal of biologic behaviour in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000;24:1125-30.
37. Kirchmann TT, Prieto VG, Smoller BR. Use of CD34 is assessing the relationship between stroma and tumour in desmoplastic keratinocyte neoplasms. J Cutan Pathol 1995;22:422-6.
38. Nakayama H, Enzan H, Miyazaki E, et al. Differential expression of CD34 in normal colorectal tissue, peritumoural inflammatory tissue and tumour stroma. J Clin Pathol 2000;53:626-9.
39. Lagios MD. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett 1995;90:97-102.
40. Page DL, Kidd TE, Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-9
41. Barth PJ, Ebrahimsade S, Ramaswamy A, et al. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ and benign breast lesions. Virchows Arch 2002;440:298-303.
42. Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast biopsy specimens and risk of breast cancer. N Engl J Med 1999;340:430-6.
43. de la Torre M, Wells AF, Bergh J, et al. Localisation of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum Pathol 1993;24:1294-7.
44. Jacobs TW, Schnitt SJ, Tan X, et al. Radial scars of the breast and breast carcinomas have similar alterations in expression of factors involved in vascular stroma formation. Hum Pathol 2002;33:29-38.
45. Parsons SL, Watson SA, Griffin NR, et al. An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 1996;7:47
46. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine 131-labelled anti-tenascin monodonal antibody 81C6 00 of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000;18:3862-72.